GAM HEALTH INNOVATION EQUITY

Marketing material for professional/institutional/accredited investors only

GAM Health Innovation Equity* aims to generate long-term capital growth through active investment in the broad healthcare sector. The fund is managed by Christophe Eggman, who seeks to identify areas of medical need that have not been met. The fund is invested in innovative companies that have incorporated strong scientific rationale into their business models in order to develop best-in-class assets.

Reasons to invest

- Long-term drivers: we believe the increasing innovation of healthcare companies, emerging markets' growth and global demographic development continue to generate attractive returns.
- Innovation drives returns: in our view, the creation of new medicines can lead to high return on investments that are both predictable and durable.
- Expansion phase: innovation and increased demand are driving expansion, with valuations at attractive levels.
- Sector consolidation: business development is a top priority for companies and investors can participate in the consolidation of the sector and its changing market dynamics.

Our edge

- Solid industry expertise: the manager has over 23 years' investment experience and a successful track record in the active management of healthcare equity.
- Dynamic industry allocation: flexible allocation across all sub-sectors of healthcare worldwide means the manager can leverage changing growth dynamics and diversify portfolio risk.
- Highly active approach: the manager takes advantage of both depressed valuations and growth opportunities, as an effective way of generating alpha.
- Skilled stock selection: the manager has proven its ability to invest early in areas of high medical need through new or improving treatments, therefore capturing as much value creation as possible.

Investment team



GAM Health Innovation Equity is managed by Christophe Eggmann who has specialist knowledge and long-term investment experience of identifying attractive opportunities in the healthcare sector.

Christophe has autonomy over the investment process and his role combines both research and fund management, however he frequently exchanges information and views with the other members of GAM's equity investment teams.

Investment risk management is primarily Christophe's responsibility, as it is an integral part of each step of the investment process and is central to the strategy. However, an additional risk oversight function is performed independently by GAM's risk teams.



Investment philosophy

The manager believes innovation is key to successful stock picking, as a potential driver of superior returns. Innovation adds value to drug development as once a medicine is commercialised it has the potential to generate substantial cash flow. This cash flow is highly predictable due to a defined patient pool, price and targeted penetration rate, and long lasting due to patent protections. The manager believes value can be achieved by investing in companies with strong fundamentals that provide growth opportunities fuelled by innovation, as well as capturing potential related to emerging markets and an ageing global population.

Investment process

The process focuses on adding value through bottom-up stock selection, based primarily on fundamental research. The manager seeks to identify innovation opportunities through the identification of top-down trends, with a focus on new growth opportunities and areas of future returns. A set of defined opportunities is established on which they assess companies, meeting up to 140 companies annually and looking at competitiveness and valuation to determine innovative companies with attractive valuations. The portfolio of approximately 50-60 stocks is diversified across sub-sectors and therapeutic indications to reduce risk. The manager uses a disciplined buy and sell process as part of its ongoing risk management function.

Fund facts

Fund type	SICAV according to Luxembourg law
Fund manager	Christopher Eggmann
Inception date	31 Jan 2008
Currency classes ¹	USD (base), CHF, EUR and GBP classes are available
Index for comparison	MSCI World Health Care ND
Dealing	Each business day
Investment manager and sponsor fees ²	A and B shares: 1.60% C shares: 0.85%

- ¹ Currency hedging may be employed to protect against exchange rate risk. Please contact your client manager for an exhaustive list of currency classes available
- ² Excludes administration and custodian fee please see the Prospectus for further details on fees.

1

Identify innovation

- Top-down identification of industry developments and trends
- Bottom-up research of innovative products and services, new markets and attractive business models

2

Assess companies

- Strong focus on management meetings and fundamental analysis
- Investment based on market share gain, high barriers to entry and valuation

3

Build portfolio

- 50-60 stocks diversified across sub-sectors
- Positions sized by conviction and actively managed and monitored

66

We value innovation by assessing the incremental benefit of a new product or service to the patient or the healthcare system."

Christophe Eggmann
Investment Director, GAM



Important legal information:

Capital at risk: All financial investments involve an element of risk. Therefore, the value of the investment and the income from it will vary and the initial investment amount cannot be guaranteed.

Currency Risk [non base currency share class]: Non-base currency share classes may or may not be hedged to the base currency of the Fund. Changes in exchange rates will have an impact on the value of shares in the Fund which are not denominated in the base currency. Where hedging strategies are employed, they may not be fully effective.

Equity: Investments in equities (directly or indirectly via derivatives) may be subject to significant fluctuations in value.

Source: GAM, unless otherwise stated. (Where applicable and, unless otherwise noted, performance is shown net of fees, on a NAV to NAV basis). GAM has not independently verified the information from other sources and GAM gives no assurance, expressed or implied, as to whether such information is accurate, true or complete.

This document is not intended for distribution to or use by persons or entities with nationality of or with their residence, domicile or registered office in a State or Country in which such distribution, publication, making available or use is contrary to laws or other regulations. The responsibility for the further use of fund descriptions contained in this document lies solely with the intermediary.

Nothing contained herein constitutes investment, legal, tax or other advice, nor is it to be solely relied on in making an investment or other decision. This document qualifies as marketing material.

The views expressed herein are those of the manager at the time and are subject to change. The price of shares may go down as well as up and the price will depend on fluctuations in financial markets outside GAM's control. As a result an investor may not get back the amount invested. Past performance is not indicative of future performance and reference to a security is not a recommendation to buy or sell that security.

This is not an invitation to invest in any GAM product or strategy. Investments should only be made after a thorough reading of the current prospectus, offering memorandum, the Key Investor Information Document "KIID", the articles of association and the current annual and semi-annual reports (the "legal documents"), as well as after consulting an independent finance and tax specialist. The legal documents can be obtained in hard copy and free of charge from the addresses indicated below.

Some of the sub-funds may not be registered for sale in all jurisdictions. Therefore, no active marketing must be carried out for them. Subscriptions will only be received and shares or units issued on the basis of the current fund prospectus.

Shares of the fund have not been registered under the US Securities Act of 1933, as amended (the "Securities Act") and the fund is not registered under the US Investment Company Act of 1940, as amended (the "Company Act"). Accordingly, such shares may not be offered, sold or distributed in the United States or to US persons unless an exemption from registration under the Securities Act and the Company Act is available. In addition, certain GAM products are closed to all US investors.

This material/presentation mentions one or several GAM Funds domiciled in Luxembourg, registered office at 25, Grand-Rue, L-1661 Luxembourg, each an umbrella investment company with variable capital and segregated liability between the sub-funds, incorporated under the laws of Luxembourg and authorised by the CSSF as a UCITS Fund in accordance with the Directive 2009/65/EC. Management Company is GAM (Luxembourg) S.A., 25, Grand-Rue, L-1661 Luxembourg.

ASIA PACIFIC: In other countries in Asia Pacific, this material should only be distributed in accordance with the applicable laws in the relevant jurisdiction.

AUSTRIA: The legal documents in English and the KIID in German can be obtained free of charge, from the Paying Agent in Austria, Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A-1010 Vienna or on the internet at www.funds.gam.com.

BULGARIA: The English version of the prospectus and the Bulgarian version of the KIID can be obtained, free of charge, on the internet at www.funds.gam.com.

CYPRUS: The English version of the prospectus and the KIID can be obtained, free of charge, on the internet at www.funds.gam.com or from the representative in Cyprus: Cyprus Development Bank Public Company Ltd, 50 Arch. Makarios III Ave., 1508 Nicosia, Cyprus.

DENMARK: This document is destined exclusively for professional or institutional investors in Denmark and shall not be passed on to third parties. Particularly, this document shall not be used as advertising material for distribution to retail investors or any other kind of public offering of the funds, their sub-funds or share categories. The English version of the prospectus, the articles of association and the most recent published annual- and semi-annual report, as well as the Danish version of the KIID, can be obtained free of charge on the internet at www.funds.gam.com.

ESTONIA: The English version of the prospectus and the Estonian version of the KIID can be obtained free of charge from the distributor: Swedbank, AS, Liivalaia 8, EE-15040 Tallinn or at www.funds.gam.com.

FINLAND: The English version of the prospectus and the Finnish version of the KIID can be obtained, free of charge, on the internet at www.funds.gam.com.

FRANCE: The prospectus, the annual report and the most recent half-yearly report in English and the KIID in French can be obtained free of charge from the centralising agent in France, CACEIS Bank, 1-3, place Valhubert – 75013 Paris or on the internet at www.funds.gam.com.

GERMANY: The legal documents in English and the KIID in German can be obtained free of charge, from the information agent GAM (Deutschland) GmbH, Taunusanlage 15, D-60325 Frankfurt am Main or on the internet at www.funds.gam.com. Paying Agent is DekaBank Deutsche Girozentrale, Hahnstrasse 55, D-60528 Frankfurt am Main. HONG KONG: In Hong Kong, this material is restricted to professional investors (as defined in the Securities and Futures Ordinance (Cap 571)) only.

ICELAND: The English version of the prospectus and the Icelandic version of the KIID can be obtained, free of charge, on the internet at www.funds.gam.com.

ITALY: This document is destined exclusively for internal use by intermediaries appointed by GAM and/or institutional or qualified investors and shall not be passed on to third parties. Particularly, this document shall not be used as advertising material for public distribution or any other kind of public offering of the funds, their sub-funds or share categories. The Prospectus, the Key Investor Information Document – KIID, the annual, the semi-annual reports as well as the subscription form and the Italian distribution partners' list of each subfund are not included in the above mentioned restriction. The English version of the prospectus and the Italian version of the KIID can be obtained, free of charge, on the internet at www.funds.gam.com.

JAPAN: In Japan, the funds mentioned herein are not registered for public sale or private placement (except for some of the funds, if applicable) pursuant to the Law on Investment Trusts and Investment Companies and shall not be disclosed publicly pursuant to the Financial Instruments and Exchange Law (the "FIEL"). Therefore, none of the Shares of the funds mentioned herein may be solicited in Japan or to residents in Japan. This material is intended for circulation to professional, institutional and/or qualified investors only. Any person in receipt of this material is not allowed to distribute it to residents in Japan nor communicate to residents in Japanwa about the funds mentioned herein.

LATVIA: The English version of the prospectus and the Latvian version of the KIID can be obtained free of charge from the authorized representative: Swedbank AS, Balasta dambis 1a, LV-1048 Riga or at www.funds.gam.com

LIECHTENSTEIN: The legal documents in English and the KIID in German, can be obtained free of charge from the paying agent Liechtenstein LGT Bank AG, Herrengasse 12, FL9490 Vaduz or on the internet at www.funds.gam.com.

LITHUANIA: The English version of the prospectus and the Lithuanian version of the KIID can be obtained free of charge from the authorized representative: Swedbank AB, Konstitucijos pr. 20A, LT - 03502 Vilnius or at www.funds.gam.com.

LUXEMBOURG: The legal documents in English can be obtained free of charge, from GAM (Luxembourg) SA or on the internet at www.funds.gam.com.

NETHERLANDS: The English version of the prospectus and the Dutch version of the KIID can be obtained free of charge on the internet at www.funds.gam.com.

NORWAY: The English version of the prospectus and the Norwegian version of the KIID can be obtained, free of charge, on the internet at www.funds.gam.com.

SPAIN: The legal documents can be obtained in English, respectively for the KIID in Spanish, free of charge, from the Paying Agent in Spain, ATL 12 Capital Inversiones A.V., S.A., Montalbán 9, 28014 Madrid or on the internet at www.funds.gam.com.

SINGAPORE: In Singapore, shares of the fund may only be offered to institutional and accredited investors (as defined in the Securities and Futures Act (Cap.289)) ('SFA') and this material is limited to the investors in those categories.

SWEDEN: The English version of the prospectus and the Swedish version of the KIID can be obtained free of charge from the Paying Agent, MFEX Mutual Funds Exchange AB, Linnégatan 9-11, SE-114 47 Stockholm or on the internet at www.funds.gam.com.

SWITZERLAND: The legal documents for: GAM Multistock can be obtained in German, free of charge, from the Swiss Representative: GAM Investment Management (Switzerland) Ltd., Hardstrasse 201, Postfach, CH-8037 Zurich or on the internet at www.funds.gam.com. Paying Agent is State Street Bank International GmbH, Munich, Zurich Branch, Beethovenstrasse 19, CH-8027 Zurich

UNITED KINGDOM: As far as UCITS described herein are recognised schemes under section 264 of the Financial Services and Markets Act 2000: Copies of the legal documents can be obtained in English, free of charge, from the Facilities Agent GAM Sterling Management Limited, 8 Finsbury Circus, London, EC2M 7GB (authorised and regulated by the FCA) or on the internet at www.funds.gam.com. Investments in the funds are not protected by the Financial Services Compensation Scheme.

Within the UK, this material has been issued and approved by GAM London Ltd, 8 Finsbury Circus, London, EC2M 7GB, authorised and regulated by the Financial Conduct Authority.